BACKGROUND: Exacerbations of COPD are a major cause of morbidity and mortality; however, it has been reported that nearly half of such episodes based on symptoms are classified as "unreported" (no change in treatment), although the reasons are unknown. METHOD: We used a symptom-based diary card to study 155 symptom-defined episodes (74 episodes in which treatment was not changed) in 19 patients with alpha(1)-antitrypsin deficiency. RESULTS: The average length for the untreated episodes (time to resolution of all symptoms) was shorter than treated episodes (mean +/- SE, 8.3 +/- 1.0 days vs 16.1 +/- 1.6 days; p < 0.001). Of most importance, the patients documented feeling less well than usual for an average of only 1.9 +/- 0.4 days for untreated episodes, vs 11.7 +/- 1.7 days for treated episodes (p < 0.001). We developed a scoring system based on the symptoms of breathlessness, well-being, sputum color, and volume to quantify the episodes. The scores were higher for the first day of the treated episodes than untreated episodes (33.5 +/- 0.6 vs 28.4 +/- 0.5, respectively; p < 0.001), and the treated episodes had total scores that exceeded the baseline more than the untreated episodes (160.5 +/- 20.0 vs 43.4 +/- 6.6; p < 0.001). Antibiotics or steroids were started 4.4 +/- 0.5 days and 4.9 +/- 1.8 days on average, respectively, after symptoms changed, suggesting that the early return of well-being to normal is central to the episodes described as unreported (untreated) by others. CONCLUSION: The diary card analysis described here provides a tool to document therapies that influence health-care-dependent exacerbations of COPD.
BACKGROUND: Exacerbations of COPD are a major cause of morbidity and mortality; however, it has been reported that nearly half of such episodes based on symptoms are classified as "unreported" (no change in treatment), although the reasons are unknown. METHOD: We used a symptom-based diary card to study 155 symptom-defined episodes (74 episodes in which treatment was not changed) in 19 patients with alpha(1)-antitrypsin deficiency. RESULTS: The average length for the untreated episodes (time to resolution of all symptoms) was shorter than treated episodes (mean +/- SE, 8.3 +/- 1.0 days vs 16.1 +/- 1.6 days; p < 0.001). Of most importance, the patients documented feeling less well than usual for an average of only 1.9 +/- 0.4 days for untreated episodes, vs 11.7 +/- 1.7 days for treated episodes (p < 0.001). We developed a scoring system based on the symptoms of breathlessness, well-being, sputum color, and volume to quantify the episodes. The scores were higher for the first day of the treated episodes than untreated episodes (33.5 +/- 0.6 vs 28.4 +/- 0.5, respectively; p < 0.001), and the treated episodes had total scores that exceeded the baseline more than the untreated episodes (160.5 +/- 20.0 vs 43.4 +/- 6.6; p < 0.001). Antibiotics or steroids were started 4.4 +/- 0.5 days and 4.9 +/- 1.8 days on average, respectively, after symptoms changed, suggesting that the early return of well-being to normal is central to the episodes described as unreported (untreated) by others. CONCLUSION: The diary card analysis described here provides a tool to document therapies that influence health-care-dependent exacerbations of COPD.
Authors: Victor Kim; Huaqing Zhao; Elizabeth Regan; MeiLan K Han; Barry J Make; James D Crapo; Paul W Jones; Jeffrey L Curtis; Edwin K Silverman; Gerard J Criner Journal: Chest Date: 2019-05-15 Impact factor: 9.410
Authors: Neil W Johnston; Andrew McIvor; Kim Lambert; Justina M Greene; Pat Hussack; Maria Gerhardsson de Verdier; Tim Higenbottam; Jonathan Lewis; Paul Newbold; Athula Herath; Martin Jenkins Journal: Can Respir J Date: 2010 Nov-Dec Impact factor: 2.409
Authors: Patricia B Koff; Sung-Joon Min; Tammie J Freitag; Debora L P Diaz; Shannon S James; Norbert F Voelkel; Derek J Linderman; Fernando Diaz Del Valle; Jonathan K Zakrajsek; Richard K Albert; Todd M Bull; Arne Beck; Thomas J Stelzner; Debra P Ritzwoller; Christine M Kveton; Stephanie Carwin; Moumita Ghosh; Robert L Keith; John M Westfall; R William Vandivier Journal: Chronic Obstr Pulm Dis Date: 2021-01
Authors: Jaap C A Trappenburg; David Schaap; Evelyn M Monninkhof; Jean Bourbeau; Gerdien H de Weert-van Oene; Theo J M Verheij; Jan-Willem J Lammers; Augustinus J P Schrijvers Journal: BMC Pulm Med Date: 2011-08-19 Impact factor: 3.317
Authors: Dave Singh; Massimo Corradi; Monica Spinola; Stefano Petruzzelli; Alberto Papi Journal: NPJ Prim Care Respir Med Date: 2016-06-16 Impact factor: 2.871
Authors: Jaap C A Trappenburg; Lieselotte Koevoets; Gerdien H de Weert-van Oene; Evelyn M Monninkhof; Jean Bourbeau; Thierry Troosters; Theo J M Verheij; Jan-Willem J Lammers; Augustinus J P Schrijvers Journal: BMC Pulm Med Date: 2009-12-29 Impact factor: 3.317